KemPharm (KMPH) Granted FDA Clearance to Initiate KP879 Clinical Program for Treatment of Stimulant Use Disorder

UPDATE: Roth Capital Starts Kempharm (KMPH) at Buy

(Updated - January 25, 2021 7:38 AM EST)

Roth Capital analyst Jonathan Aschoff initiates coverage on Kempharm (NASDAQ: KMPH) with a Buy rating and a price target of $28.00.

The analyst comments "KemPharm is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of... More